15 U.S.C. § 78j(b); 17 C.F.R. § 240.10b-5
Securities fraud under Rule 10b-5: the implied claim Congress spent a statute constraining
A federal claim in United States district courts · Last verified August 26, 2026
The most heavily litigated private claim in federal securities law appears nowhere in any statute. Congress prohibited manipulative and deceptive devices; the SEC wrote a rule; and courts implied a private damages action neither had provided for.
Everything that follows is shaped by that origin. The Supreme Court has narrowed the claim repeatedly, Congress passed an entire statute to constrain it, and the pleading standard is the strictest in federal civil practice.
What the claim is
Someone lied, or misleadingly half-told the truth, in connection with your purchase or sale of a security, and the stock dropped when the truth came out.
Almost all of these are class actions following a stock-price collapse: an accounting misstatement, a concealed regulatory problem, an overstated product prospect, a failed clinical trial the company knew about and did not disclose.
Where the right comes from
Implied. The Court recognised the action in the 1970s and by 1983 described its existence as "beyond peradventure" — settled by acquiescence rather than by design.
Since then the trend has run one way, narrowing:
- No aiding-and-abetting liability in a private action.
- Only the "maker" of a statement is primarily liable — the person with ultimate authority over it — though scheme liability survives for those who disseminate it.
- No liability for pure omissions. In Macquarie Infrastructure Corp. v. Moab Partners (2024) the Court held unanimously that failing to disclose information a regulation required "cannot support a private claim under Rule 10b-5(b) in the absence of an otherwise-misleading statement." The Rule "covers half-truths, not pure omissions." A plaintiff must now tie the silence to something the company said.
What a plaintiff has to prove
Six elements:
- A material misrepresentation or actionable omission.
- Scienter — an intent to deceive, manipulate, or defraud. Negligence never suffices.
- In connection with the purchase or sale of a security.
- Reliance, ordinarily presumed for publicly traded stock under the fraud-on-the-market theory.
- Economic loss.
- Loss causation — that the misstatement, not some other market event, caused the loss.
The pleading standard is two layers deep, and both apply. Ordinary fraud particularity, plus the stricter requirements Congress added: the complaint must specify each statement alleged to have been misleading and state with particularity facts giving rise to a strong inference of the required state of mind. Under Tellabs v. Makor Issues & Rights, that inference must be "cogent and at least as compelling as any opposing inference of nonfraudulent intent" — the court weighs the innocent explanation against yours at the pleading stage, which is not how pleading normally works.
How long you have to file
Two years from discovery, five years from the violation, whichever comes first.
The two-year clock runs from when a reasonably diligent plaintiff would have discovered the facts constituting the violation — including scienter, under Merck & Co. v. Reynolds. Suspicious circumstances alone do not start it.
The five-year period is a statute of repose and it cannot be tolled by anything. In California Public Employees' Retirement System v. ANZ Securities the Court held the filing of a class action does not extend the repose period for an individual investor who later opts out. A class member who waits for the class case to resolve, then files their own suit, can find the claim extinguished even though the class action was filed in time. This has cost institutional investors real money and it is the single most consequential timing trap in the area.
What has to happen before you file
No administrative exhaustion. But two statutory gates shape the case from the first day:
The lead-plaintiff process. The first filer publishes notice, investors move to be appointed lead plaintiff, and the court selects the one with the largest financial interest. The named plaintiff who filed first often is not the one who ends up running the case.
The automatic discovery stay. All discovery is stayed while a motion to dismiss is pending. That inverts the usual leverage — a securities defendant can test the complaint without producing a single document, and a plaintiff must plead scienter with particularity before obtaining any discovery to support it.
Character: both are mandatory statutory case-management rules, not jurisdictional.
Who can be sued — and who cannot
Issuers, officers and directors, and others who made an actionable statement.
Only actual purchasers or sellers may sue. Someone who read the misstatement and decided not to buy has no claim, however real the loss of opportunity — the rule from Blue Chip Stamps v. Manor Drug Stores, adopted to keep the claim's boundaries administrable.
No private aiding-and-abetting defendants. Accountants, bankers, and lawyers who helped are not liable in a private suit unless they made a statement themselves or participated in a scheme. The SEC can reach them; private plaintiffs cannot.
Common defenses
The safe harbour for forward-looking statements. A projection is not actionable if identified as forward-looking and accompanied by meaningful cautionary language — or if the plaintiff cannot prove it was made with actual knowledge of falsity. This defeats a great many claims about guidance and projections at the pleading stage.
No strong inference of scienter, which is where most complaints fail.
No loss causation — the price drop had another cause.
Truth on the market, and rebutting price impact with evidence that the alleged misstatement did not move the stock, which the Court confirmed defendants may do at class certification.
Puffery — vague optimism no reasonable investor relies on.
What the claim pays
Actual out-of-pocket damages, subject to a statutory cap: recovery is limited using a 90-day look-back on the average price after corrective disclosure, so a plaintiff cannot capture a post-disclosure overshoot.
Rescission is available in some circumstances. Jury trial available.
Fee-shifting runs only through sanctions. There is no prevailing-party fee provision. What Congress did instead was make sanctions review mandatory — at the end of every case the court must determine whether the pleadings complied with the certification rule, which is a real deterrent on both sides.
What people get wrong
"Failing to disclose something a regulation required is securities fraud." Not by itself, after Macquarie. You need an otherwise-misleading statement.
"Filing a class action protects my individual claim." It does not extend the five-year repose period, after ANZ.
"Negligence is enough." No. Scienter is required.
"I didn't buy because of the lie, so I'll sue." Only purchasers and sellers have standing.
"The auditors signed off, so they're liable too." Not in a private action unless they made a statement or joined a scheme.
"I can get discovery to prove scienter." Not while a motion to dismiss is pending.
Where it came from
Section 10(b) was enacted in 1934; the SEC adopted Rule 10b-5 in 1942, reportedly in an afternoon, to close a gap covering purchases as well as sales. Courts implied the private action, and by the 1980s it had grown into the dominant private securities remedy.
Congress then overrode the resulting litigation regime directly. The Private Securities Litigation Reform Act of 1995 imposed the heightened pleading standard, the lead-plaintiff process, the discovery stay, the safe harbour, and the damages cap — a deliberate constriction of a judge-made claim. When plaintiffs responded by filing in state court, Congress closed that route too in 1998. Sarbanes-Oxley set the current two- and five-year periods in 2002.
The result is unusual: a cause of action courts invented, that Congress never created but has twice legislated to restrain.
Common questions
What is the deadline for a securities fraud claim?
Two years from when you discovered or should have discovered the facts, and no more than five years from the violation. Whichever expires first controls.
Can a class action filing protect my individual claim?
Not against the five-year period. That is a statute of repose and cannot be tolled, so an investor who opts out and files late may find the claim extinguished.
Is a company liable for failing to disclose bad news?
Not on its own. After Macquarie Infrastructure Corp. v. Moab Partners, a pure omission is not actionable under Rule 10b-5(b) — the silence must render something the company said misleading.
Do I have to have bought or sold the stock?
Yes. Only actual purchasers and sellers have standing. Deciding not to buy because of a misrepresentation does not create a claim.
Why can't I get documents before the motion to dismiss is decided?
Because discovery is automatically stayed while that motion is pending. You must plead scienter with particularity first, using facts obtained without discovery.